MK-7655 (Relebactam) + Imipenem/Cilastatin
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-7655 (Relebactam) + Imipenem/Cilastatin, covering 2019-05-24 to 2019-05-24. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) [Phase 2]